Development of an Interpretable QSAR Model for Predicting Coagulation Factor XIIa Inhibitors Using Ensemble Machine Learning
Open Access
- 9 September 2026
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (9) , 1426
Abstract
Background/Objective: Activated coagulation factor XII (FXIIa) is a component of the contact activation pathway and a pharmacologically relevant target in contact-system-associated processes. In this study, scaffold-aware and interpretable machine-learning QSAR models were developed for human FXIIa activity. Methods: Bioactivity records for the human single protein target CHEMBL2821 were retrieved from ChEMBL release 37. Modeling was restricted to exact IC50 measurements from assays explicitly referring to FXIIa, Factor XIIa, or activated Factor XII. Median-consolidated pIC50 values and two-dimensional Mordred descriptors were evaluated using leakage-safe preprocessing, scaffold-disjoint validation, Y-randomization, applicability domain analysis, structural similarity auditing, and SHAP interpretation. Results: The regression dataset comprised 424 compounds and 166 Bemis–Murcko scaffolds in this study. The Gradient Boosting regressor achieved R2 = 0.7560, RMSE = 0.6924, and MAE = 0.4965 on the locked scaffold-disjoint test set (n = 85); across 50 repeated scaffold partitions, the mean R2 was 0.6892 ± 0.1515. The classification model achieved ROC-AUC = 0.9453, PR-AUC = 0.9807, balanced accuracy = 0.7561, and MCC = 0.5972 (n = 73). Y-randomization supported nonrandom predictive signals (empirical p = 0.0099). Conclusions: The models support computational prioritization within the represented FXIIa chemical domain, while prospective evaluation of independently generated compounds remains necessary.Keywords
This publication has 56 references indexed in Scilit:
- Interpretable machine learning-driven QSAR modeling for coagulation factor X inhibitors: from molecular descriptors to predictive potencyJournal of Computer-Aided Molecular Design, 2026
- Scaffold Splits Overestimate Virtual Screening Performance2024
- Microscale Parallel Synthesis of Acylated Aminotriazoles Enabling the Development of Factor XIIa and Thrombin InhibitorsChemMedChem, 2021
- Factor XII/XIIa inhibitors: Their discovery, development, and potential indicationsEuropean Journal of Medicinal Chemistry, 2020
- Factor XII – What's important but not commonly thought aboutResearch and Practice in Thrombosis and Haemostasis, 2019
- Factor XII in coagulation, inflammation and beyondCellular Signalling, 2018
- Identifying novel factor XIIa inhibitors with PCA-GA-SVM developed vHTS modelsEuropean Journal of Medicinal Chemistry, 2017
- Best Practices for QSAR Model Development, Validation, and ExploitationMolecular Informatics, 2010
- Principles of QSAR models validation: internal and externalQSAR & Combinatorial Science, 2007
- Extremely randomized treesMachine Learning, 2006